Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Looks To Outcomes Research In Move To Quantify Risk/Benefit Decisions

Executive Summary

Outcomes trials appear to hold a strong position in the future of new drug development. But outcomes data is not the only factor FDA will consider as it moves toward setting new standards for quantification of risk and benefit, the agency said at a recent drug safety conference

You may also be interested in...



Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA

The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference

Don’t Forget Injectable Insulin, Novo Nordisk Says

In the rush to develop new diabetes drugs, big pharma's focus has been mainly on anti-diabetic agents that prolong a patient's transition to insulin or on developing easier routes of administration for insulin that do away with the need for pesky needles

Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA

The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference

Related Content

UsernamePublicRestriction

Register

PS050314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel